Department of Oncological Sciences, Tish Cancer Institute, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.
Adv Exp Med Biol. 2024;1465:15-36. doi: 10.1007/978-3-031-66686-5_2.
Breast cancer (BC) poses significant challenges, driven by its diverse nature and intricate dynamics. Epigenetic modifications, such as DNA methylation, histone modifications, and noncoding RNAs, have emerged as key regulators of gene expression and BC metastasis plasticity or therapeutic resistance. Targeting epigenetic regulators and pathways associated with therapeutic resistance holds promise for overcoming treatment obstacles and enhancing treatment efficacy.
乳腺癌（BC）具有显著的挑战性，其多样性和复杂动态是主要驱动因素。表观遗传修饰，如 DNA 甲基化、组蛋白修饰和非编码 RNA，已成为基因表达和 BC 转移可塑性或治疗耐药性的关键调控因子。针对与治疗耐药性相关的表观遗传调控因子和途径，有望克服治疗障碍，提高治疗效果。
